As of November 6, 2026, Tvardi Therapeutics, Inc. is a publicly traded company (Nasdaq: TVRD); its largest reported holder is Sporos Bioventures LLC, with 8.95% on Schedule 13G of August 8, 2025, then Slate Path Capital LP (7.5%) (Schedule 13G, August 8, 2025).
Is this your company?
About to sign with, pay or invest in Tvardi Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Tvardi Therapeutics, Inc. a real, registered company?
- Tvardi Therapeutics, Inc. files with the SEC under CIK 1346830 (its SEC filings).
- Its shares are listed under the ticker TVRD on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Sugar Land, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under TVARDI THERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Ronald A. DePinho (filed 2025-11-14).
Who are Tvardi Therapeutics, Inc.'s owners and officers?
Tvardi Therapeutics, Inc.: incorporated in Delaware; business address in Sugar Land, Texas; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-02-17).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-02-17 | Ronald A. Depinho | 4.5% |
| Schedule 13G/A, 2025-11-14 | Ronald A. Depinho | 6.7% |
| Schedule 13G, 2025-08-14 | Slate Path Capital LP | 7.5% |
| Schedule 13G, 2025-08-08 | Sporos Bioventures LLC | 8.95% |
| Schedule 13G/A, 2025-08-05 | Samuel D. Tweardy | 3.4% |
Questions about who owns Tvardi Therapeutics, Inc.
Who owns Tvardi Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Tvardi Therapeutics, Inc.: Sporos Bioventures LLC (8.95%, Schedule 13G, filed 2025-08-08) and Slate Path Capital LP (7.5%, Schedule 13G, filed 2025-08-14).
Who are the largest shareholders of Tvardi Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Tvardi Therapeutics, Inc. on this page are Sporos Bioventures LLC (8.95%) and Slate Path Capital LP (7.5%).
When did Sporos Bioventures LLC buy into Tvardi Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Sporos Bioventures LLC on this page is the Schedule 13G, filed 2025-08-08, reporting 8.95%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Tvardi Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Tvardi Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tvardi Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Tvardi Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 439,194 shares (3.3% of shares outstanding), held indirectly through Palkon TT Holdings, LLC and 1 other (Form 4/A, 2025-05-02).
- , a director: 246,756 shares (1.8% of shares outstanding), held indirectly through Firepit Partners, LP and 1 other (Form 4/A, 2025-05-02).
- , the chief executive and president: 13,109 shares (0.10% of shares outstanding) (Form 4, 2025-03-04).
- , the sec'y and chief compliance: 7,190 shares (0.05% of shares outstanding) (Form 4, 2025-03-04).
Shares outstanding: 13,338,943 as of 2026-08-11, from the company's latest SEC cover page.
How much has Tvardi Therapeutics, Inc. raised?
Latest IPO step: Tvardi Therapeutics, Inc. amended its IPO registration (S-1/A, 2025-10-20).
IPO filings: S-1/A, 2025-10-20, S-1/A, 2025-10-07, S-1, 2025-05-30; ticker TVRD on Nasdaq Capital Market.
Keep reading
More on Tvardi Therapeutics, Inc. and the records around it.
Tvardi Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
Companies that share a holder
- Slate Path Capital LP also filed stake reports on 2 other companies: WOLFSPEED, INC. (May 2026), Rocket Companies, Inc. (Oct 2025)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/tvardi-therapeutics